Terms: = Endocrine gland cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Treatment
790 results:
1. Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors.
Cheng Y; Dai Y; Tang H; Lu X; Xie J; Xie W; Zhang Q; Liu Y; Lin S; Yao H; Shang H; Yang K; Liu H; Wu X; Zhang J; Zhang X; Xue L; Wu ZB
Acta Neuropathol Commun; 2024 Apr; 12(1):61. PubMed ID: 38637883
[TBL] [Abstract] [Full Text] [Related]
2. Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line.
Çoban HŞ; Çil N; Önder E; Abban Mete G
Mol Biol Rep; 2024 Apr; 51(1):485. PubMed ID: 38578399
[TBL] [Abstract] [Full Text] [Related]
3. Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis.
Cigrovski Berkovic M; Coppola A; Sesa V; Mrzljak A; Lai Q
World J Gastroenterol; 2024 Feb; 30(7):759-769. PubMed ID: 38515954
[TBL] [Abstract] [Full Text] [Related]
4. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mtor signaling axis by binding to MYH9.
Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
[TBL] [Abstract] [Full Text] [Related]
5. A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer.
Zhu SL; Qi M; Chen MT; Lin JP; Huang HF; Deng LJ; Zhou XW
Phytomedicine; 2024 Jun; 128():155377. PubMed ID: 38503154
[TBL] [Abstract] [Full Text] [Related]
6. PIK3R1 fusion drives chemoresistance in ovarian cancer by activating ERK1/2 and inducing rod and ring-like structures.
Rausio H; Cervera A; Heuser VD; West G; Oikkonen J; Pianfetti E; Lovino M; Ficarra E; Taimen P; Hynninen J; Lehtonen R; Hautaniemi S; Carpén O; Huhtinen K
Neoplasia; 2024 May; 51():100987. PubMed ID: 38489912
[TBL] [Abstract] [Full Text] [Related]
7. Evaluating synergistic effects of metformin and simvastatin on ovarian cancer cells.
Mikhael S; Kurdi A; Khoueiry-Zgheib N; Tahtouh R; Nasr R; Hilal G
PLoS One; 2024; 19(3):e0298127. PubMed ID: 38489280
[TBL] [Abstract] [Full Text] [Related]
8. Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts.
Arakawa Y; Jo U; Kumar S; Sun NY; Elloumi F; Thomas A; Roper N; Varghese DG; Takebe N; Zhang X; Ceribelli M; Holland DO; Beck E; Itkin Z; McKnight C; Wilson KM; Travers J; Klumpp-Thomas C; Thomas CJ; Hoang CD; Hernandez JM; Del Rivero J; Pommier Y
Cancer Res Commun; 2024 Mar; 4(3):834-848. PubMed ID: 38451783
[TBL] [Abstract] [Full Text] [Related]
9. Defects of mitochondria-lysosomes communication induce secretion of mitochondria-derived vesicles and drive chemoresistance in ovarian cancer cells.
Gagliardi S; Mitruccio M; Di Corato R; Romano R; Aloisi A; Rinaldi R; Alifano P; Guerra F; Bucci C
Cell Commun Signal; 2024 Mar; 22(1):165. PubMed ID: 38448982
[TBL] [Abstract] [Full Text] [Related]
10. TOP2A modulates signaling via the AKT/mtor pathway to promote ovarian cancer cell proliferation.
Zhang K; Zheng X; Sun Y; Feng X; Wu X; Liu W; Gao C; Yan Y; Tian W; Wang Y
Cancer Biol Ther; 2024 Dec; 25(1):2325126. PubMed ID: 38445610
[TBL] [Abstract] [Full Text] [Related]
11. Glycolysis-non-canonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment.
Qiao J; Liu S; Huang Y; Zhu X; Xue C; Wang Y; Xiong H; Yao J
J Colloid Interface Sci; 2024 Jul; 665():477-490. PubMed ID: 38429120
[TBL] [Abstract] [Full Text] [Related]
12. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer.
Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
[TBL] [Abstract] [Full Text] [Related]
13. The miR-1290/OGN axis in ovarian cancer-associated fibroblasts modulates cancer cell proliferation and invasion.
Jiang B; Xiao S; Zhang S; Xiao F
J Ovarian Res; 2024 Feb; 17(1):52. PubMed ID: 38402185
[TBL] [Abstract] [Full Text] [Related]
14. Complexity of the Genetic Background of Oncogenesis in Ovarian cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract] [Full Text] [Related]
15. Deep response to a combination of mtor inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with
Oh Y; Park JH; Djunadi TA; Shah Z; Chung LI; Chae YK
Front Endocrinol (Lausanne); 2024; 15():1304188. PubMed ID: 38356955
[TBL] [Abstract] [Full Text] [Related]
16. GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells.
Zhang X; Zhang L; Wang B; Zhang X; Gu L; Guo K; Zhang X; Zhou Z
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):221-225. PubMed ID: 38279433
[TBL] [Abstract] [Full Text] [Related]
17. PW06 suppresses cancer cell metastasis in human pancreatic carcinoma MIA PaCa-2 cells via the inhibitions of p-Akt/mtor/NF-κB and MMP2/MMP9 signaling pathways in vitro.
Huang YP; Yeh CA; Ma YS; Chen PY; Lai KC; Lien JC; Hsieh WT
Environ Toxicol; 2024 May; 39(5):2768-2781. PubMed ID: 38264921
[TBL] [Abstract] [Full Text] [Related]
18. Hypoxia upregulating ACSS2 enhances lipid metabolism reprogramming through HMGCS1 mediated PI3K/AKT/mtor pathway to promote the progression of pancreatic neuroendocrine neoplasms.
Gu D; Ye M; Zhu G; Bai J; Chen J; Yan L; Yu P; Lu F; Hu C; Zhong Y; Liu P; He Q; Tang Q
J Transl Med; 2024 Jan; 22(1):93. PubMed ID: 38263056
[TBL] [Abstract] [Full Text] [Related]
19. Comprehensive Analysis of MICALL2 Reveals Its Potential Roles in EGFR Stabilization and Ovarian cancer Cell Invasion.
Xia T; Ye F; Zhao W; Min P; Qi C; Wang Q; Zhao M; Zhang Y; Du J
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203692
[TBL] [Abstract] [Full Text] [Related]
20. Bioactive Properties of
Rivas-García L; Crespo-Antolín L; Forbes-Hernández TY; Romero-Márquez JM; Navarro-Hortal MD; Arredondo M; Llopis J; Quiles JL; Sánchez-González C
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203451
[No Abstract] [Full Text] [Related]
[Next]
